Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

156
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
156
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

266
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
266
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

145
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
145
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

121
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
121
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

139
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
139
Esophagus01:24

Esophagus

1.2K
The esophagus, a muscular conduit linking the pharynx and stomach, measures roughly 10 inches (25.4 cm) and sits behind the trachea. It remains collapsed when not swallowing. The esophagus follows a predominantly straight path through the thoracic mediastinum and enters the abdominal cavity through a diaphragmatic opening known as the esophageal hiatus.
The movement of edibles from the pharynx into the esophagus is facilitated by the upper esophageal sphincter, which is formed primarily by the...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Samsung Health Monitor App for the Detection of Obstructive Sleep Apnea.

American family physician·2026
Same author

Endometrial Cancer: Rapid Evidence Review.

American family physician·2025
Same author

Early Childhood Concerns: Counseling on Sleep Issues, Thumb-Sucking, Picky Eating, School Readiness, and Oral Health.

American family physician·2025
Same author

Pancreatic Cancer: Rapid Evidence Review.

American family physician·2024
Same author

FilmArray GI Panel in the Assessment of Acute Gastroenteritis.

American family physician·2024
Same author

Risk of Ovarian Malignancy Algorithm (ROMA) for Assessing Likelihood of Ovarian Cancer.

American family physician·2023

Related Experiment Video

Updated: Aug 25, 2025

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.1K

Barrett Esophagus: Rapid Evidence Review.

Carl Bryce1, Merima Bucaj1, Renee Gazda1

  • 1Abrazo Family Medicine Residency, Phoenix, Arizona.

American Family Physician
|October 19, 2022
PubMed
Summary

Barrett esophagus, a precancerous esophageal condition, affects millions. Early detection and management, including endoscopic treatment and PPIs, are crucial for preventing esophageal adenocarcinoma.

Area of Science:

  • Gastroenterology
  • Oncology
  • Preventive Medicine

Background:

  • Barrett esophagus is a premalignant esophageal condition affecting up to 5.6% of the U.S. population.
  • Risk factors include gastroesophageal reflux disease, obesity, age over 50, male sex, smoking, and family history.
  • Malignant transformation to esophageal adenocarcinoma is rare without dysplasia.

Purpose of the Study:

  • To outline the diagnosis, management, and surveillance of Barrett esophagus.
  • To highlight risk factors and screening recommendations.
  • To discuss the role of medications in managing Barrett esophagus and associated risks.

Main Methods:

  • Diagnosis involves upper endoscopy with biopsies to identify mucosal changes and dysplasia.
  • Management strategies depend on dysplasia severity, including endoscopic treatment.

More Related Videos

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

12.1K
Surgical Models of Gastroesophageal Reflux with Mice
05:19

Surgical Models of Gastroesophageal Reflux with Mice

Published on: August 25, 2015

10.2K

Related Experiment Videos

Last Updated: Aug 25, 2025

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.1K
Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

12.1K
Surgical Models of Gastroesophageal Reflux with Mice
05:19

Surgical Models of Gastroesophageal Reflux with Mice

Published on: August 25, 2015

10.2K
  • Surveillance aims to detect dysplasia and early-stage esophageal adenocarcinoma.

    • Main Results:

    • Endoscopic treatment of dysplasia reduces malignant transformation risk.
    • Proton pump inhibitors manage reflux and may lower adenocarcinoma risk.
    • Statins, NSAIDs, and aspirin show potential risk reduction but lack definitive indications.

    Conclusions:

    • Barrett esophagus requires vigilant management, tailored to dysplasia presence and severity.
    • Screening is recommended for individuals with chronic reflux and additional risk factors.
    • While certain medications show promise, their use should be based on established indications; mortality benefits of screening and surveillance remain uncertain.